EpiCept To Release New Findings For Ceplene Drug

EpiCept is expected to release the new findings demonstrating the pharmacoeconomic benefits of Ceplene (histamine dihydrochloride) for the remission maintenance of Acute Myeloid Leukemia (AML) patients in first remission.

These data will be presented in two separate poster presentations on October 25 and 27, 2009 in Paris, France at the Twelfth Annual European Congress of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR).

The company said that the researchers from Applied Healthcare Resource Management has analysed the data from the pivotal phase III clinical trial for Ceplene to determine the incremental cost effectiveness of Ceplene with low-dose interleukin-2 (IL-2) versus current standard of care for remission maintenance of AML patients in first complete remission.

Jack Talley, president and CEO of EpiCept, said: “As the only therapy approved in Europe to maintain first remission in AML patients, we believe Ceplene can play a unique role in addressing this deadly disease. We commissioned this study to further validate the commercial potential of Ceplene to prospective partners, and guide the pricing and reimbursement rationale for this innovative medicine.”